Broken Heart Or Takotsubo Syndrome Can Cause Lasting Damage To The Heart Muscle
In the United Kingdom, more than 3,000 people are being affected every year with the "broken heart syndrome" (also known as Takotsubo syndrome or Takotsubo cardiomyopathy). These symptoms are similar to heart attack and syndrome.
A study shows women are mostly affected with the "broken heart syndrome". Till now, healthcare professionals are thinking that the muscles of the heart will fully recover after the "broken heart syndrome" without medical intervention.
A current study at the Aberdeen University, Aberdeen, the United Kingdom shows long-lasting damage to the heart and a temporary muscle failure with the "broken heart syndrome".
The "broken heart syndrome" may be triggered by emotional distress (caused due to a sudden rush of hormones). The life expectancy of an individual with "broken heart syndrome" is similar to a patient with a heart attack.
Studies show that between three percent and 17 percent of the people die due to "broken heart syndrome" within five years of diagnosis. About 90 percent of the affected patients are women. The stressful triggers for the "broken heart syndrome" was identified in about 70 percent of them.
A study on 52 patients with "broken heart syndrome" using cardiac MRI scans and ultrasound shows that the pumping and the squeezing action of muscles are affected with "broken heart syndrome". They also observed the fine scars in some parts of the heart muscle and those scars are causing a reduction in the elasticity of the muscles of the heart. A reduction in the elasticity of the heart muscle can prevent a normal muscle contraction of the heart.
The authors of the study say that this study shows the need to find out effective treatment for the "broken heart syndrome".
The lead author of the study was Dr. Dana Dawson, Reader in Cardiovascular Medicine, the Aberdeen University, Aberdeen, the United Kingdom. The study was published in the Journal of the American Society of Echocardiography (JASE). Title of the article is "Alterations in Cardiac Deformation, Timing of Contraction and Relaxation, and Early Myocardial Fibrosis Accompany the Apparent Recovery of Acute Stress-Induced (Takotsubo) Cardiomyopathy An End to the Concept of Transience". The British Heart Foundation (BHF) has funded this project.
The AT04A Vaccine Can Lower The LDL Cholesterol In The Arteries And Can Prevent Atherosclerosis And Heart Diseases
The scientists at the AFFiRis, Austria, have done a successful therapy on mice models with the AT04A vaccine to protect them against the build-up of cholesterol in the arteries. This therapy is using the immune system to stop the low-density lipoprotein cholesterol (LDL) or bad cholesterol in the arteries.
The AT04A vaccine will guide our immune system in fighting with an enzyme called PCSK9 (Proprotein convertase subtilisin/Kexin type 9). The enzyme called PCSK9 inhibitors can stop the process of natural cleaning of LDL or bad cholesterol from our arteries.
The study shows the following benefits in mice models with AT04A vaccine when compared to non-vaccinated mice models.
Now to find out the safety of humans with the AT04A vaccine, the scientists are conducting a Phase I trial on 72 people. The study is going to be completed by the end of 2017.
The co-author of the study was Dr. Gnther Staffler, the chief technology officer at AFFiRis, Austria. The study was published in the Oxford Academic Journals. Title of the article is "The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice".
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.